BD Q2 FY2026 revenue $4.7B (+5.2% reported), GAAP EPS $(0.13), adj. EPS $2.90; raises FY adj. EPS guidance

BECTON DICKINSON & CO

2026-Q2 EPS reported $0.25 revenue$9,200,000,000

Revenue $4,714M, +5.2% reported/2.6% FX-neutral; GAAP diluted EPS $(0.13) from continuing ops vs $0.55 prior year.
Adjusted diluted EPS $2.90, up from $2.79 (+3.9% reported); company raises full-year adjusted EPS guidance.
Executed $2.0B accelerated share repurchase and retired $2.1B of debt in the quarter.
Reaffirms revenue growth guidance; more than 90% of business delivered mid-single-digit growth.
Spin-off of Biosciences & Diagnostic Solutions completed Feb 9, 2026; results reflect continuing ops.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BECTON DICKINSON & CO reported second fiscal quarter ending March 31, 2026 results: revenue $4,714, EPS $(0.13) and $2.90. Guidance raised.

Period: second fiscal quarter ending March 31, 2026
Revenue: $4,714
EPS: $(0.13) and $2.90
Guidance: raised
Result: reported results

Exact text from the filing

Fiscal 2026 Operating Results Three Months Ended March 31, Reported Change Foreign Currency Neutral Change 1 (Millions of dollars, except per share amounts) 2026 2025 Revenues $ 4,714 $ 4,480 5.2 % 2.6 % Reported Diluted Earnings per Share $ (0.13) $ 0.55 (123.6) % (130.9) % Adjusted Diluted Earnings per Share 1 $ 2.90 $ 2.79 3.9 % 1.1 % 1 Represents a non-GAAP

View on SEC.gov

Browse all earnings releases →

BECTON DICKINSON & CO filing history →

Source: SEC EDGAR

accession 0001628280-26-031638

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.